Mylan (MYL) Gets FDA Ok for Generic Prevacid
More News related to MYL
- Mylan Awarded NABP-VAWD Accreditation for Its Primary North American Distribution Facility
- Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
- Oppenheimer Starts Mylan (MYL), Warner Chilcott (WCRX) at Outperform
- Mylan Schedules Fourth Quarter 2009 Financial Results Conference Call and Live Webcast
- Mylan (MYL) Gets OK from U.S. FDA for ANDA for Generic Form of GoLytely
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
Mylan Inc. (Nasdaq: MYL) received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR) Capsules, 15 mg and 30 mg. This product is shipping immediately and will be sold under the Mylan Pharmaceuticals brand.
Lansoprazole DR Capsules are the generic version of Tap Pharmaceuticals' proton pump inhibitor Prevacid® DR Capsules.
Related Categories
FDAStocks Mentioned
-0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
